Login / Signup

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305).

Lauren C PowellGilbert L'ItalienEvan PopoffKarissa JohnstonFiona O'SullivanLinda HarrisRobert CroopVladimir CoricRichard B Lipton
Published in: Advances in therapy (2022)
NCT03732638.
Keyphrases
  • open label
  • clinical trial
  • healthcare
  • public health
  • double blind
  • randomized controlled trial
  • phase ii
  • combination therapy
  • mass spectrometry
  • health promotion
  • human health